SCHEMBL7068692

SCHEMBL7068692

OCCc1ccccc1NCCOc1cc2[nH]c3ccccc3c2cc1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.39
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
ATM Q13315 2/20 0.36
MAPT P10636 2/20 0.36
UTS2R Q9UKP6 2/20 0.35
HSD17B10 Q99714 1/20 0.35
AHR P35869 1/20 0.35
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRA5 P31644 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7781300 0.89 NR1I2 (0.33) ADRB2KDM4EALDH1A1HPGDMEN1
SCHEMBL7070291 0.88 ADRB2 (0.38) ADRB2KDM4EALDH1A1HPGDMEN1
SCHEMBL7778752 0.88 KDM4E (0.38) ADRB2KDM4EALDH1A1HPGDMEN1
SCHEMBL7069437 0.84 KDM4E (0.42) ADRB2KDM4EALDH1A1HPGDMEN1
SCHEMBL6905932 0.84 CTSV (0.41) ADRB2KDM4EALDH1A1HPGDUTS2R
SCHEMBL7983732 0.82 TP53 (0.39) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL7068696 0.80 ADRB2 (0.44) ADRB2KDM4EKMT2AATMMAPT
SCHEMBL7072937 0.76 KIF11 (0.36) KDM4EALDH1A1HPGDPOLBHSD17B10
SCHEMBL7160495 0.74 ADRB2 (0.31) ADRB2
SCHEMBL7070543 0.72 MTNR1A (0.50) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
US-20030073644-A1 Combinations comprising a beta-agonist and a further antidiabetic agent SMITHKLINE BEECHAM P.L.C. 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 ADRB2 14/4885KDM4E 2447/4885ALDH1A1 1815/4885
US-20030073644-A1 Combinations comprising a beta-agonist and a further antidiabetic agent ADRB1, ADRB2, ADRB3 ADRB2 2/4885KDM4E 4572/4885ALDH1A1 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.